<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00824785</url>
  </required_header>
  <id_info>
    <org_study_id>CCR3024</org_study_id>
    <nct_id>NCT00824785</nct_id>
  </id_info>
  <brief_title>REAL3 Trial of Efficacy of EOX With/Without Panitumumab in Previously Untreated Adv OG Cancer</brief_title>
  <acronym>REAL3</acronym>
  <official_title>REAL 3 : A Randomised Open-labelled Multicentre Trial of the Efficacy of Epirubicin, Oxaliplatin and Capecitabine (EOX) With or Without Panitumumab in Previously Untreated Advanced Oesophago-gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Royal Marsden NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Royal Marsden NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine whether adding panitumumab, an antibody against the epidermal growth factor&#xD;
      receptor (EGFR), to standard chemotherapy with epirubicin, oxaliplatin and capecitabine&#xD;
      (EOX), improves the duration of survival of patients with advanced stomach and oesophageal&#xD;
      cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multicentre phase III, open labelled, randomised controlled trial. Randomisation will be 1:1&#xD;
      Arm A EOX and Arm B EOX + panitumumab. There will be a pilot phase II study of which the&#xD;
      first 200 patients will be randomised and the primary endpoint for interim analysis will be&#xD;
      when these patients have completed 6 months follow-up&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Lack of efficacy&#xD;
  </why_stopped>
  <start_date>May 2008</start_date>
  <completion_date type="Anticipated">February 2013</completion_date>
  <primary_completion_date type="Anticipated">February 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Early termination</time_frame>
    <description>Study closed early due to lack of efficacy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>response rate, toxicity, quality of life and PFS</measure>
    <time_frame>Early termination</time_frame>
    <description>Study closed early due to lack of efficacy</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">574</enrollment>
  <condition>Oesophago-gastric Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A EOX</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>EOX chemotherapy (epirubicin, oxaliplatin and capecitabine)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B EOX + panitumumab.</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>EOX chemotherapy with the addition of panitumumab 9mg/kg every 21 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>epirubicin, oxaliplatin, capecitabine (EOX)</intervention_name>
    <description>epirubicin 50mg/m(2) IV on day 1 oxaliplatin 130mg/m(2) IV on day 1 with hydration capecitabine 1250mg/m(2)/day PO in two divided doses continuously from days 1-21</description>
    <arm_group_label>Arm A EOX</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EOX + panitumumab</intervention_name>
    <description>epirubicin 50mg/m(2) IV on day 1 oxaliplatin 100mg/m(2) IV on day 1 with hydration capecitabine 1000mg/m(2)/day PO in two divided doses continuously from days 1-21 panitumumab -9 mg/kg every 21 days</description>
    <arm_group_label>Arm B EOX + panitumumab.</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically verified inoperable locally advanced or metastatic adenocarcinoma or&#xD;
             undifferentiated carcinoma of the oesophagus, oesophago-gastric junction, or stomach.&#xD;
&#xD;
          -  Slides of tumour tissue should be available for centralised EGFR staining&#xD;
&#xD;
          -  Uni-dimensionally measurable disease (CT or MRI as per RECIST).&#xD;
&#xD;
          -  No prior chemotherapy including previous adjuvant chemotherapy&#xD;
&#xD;
          -  No prior radiotherapy including adjuvant radiotherapy. Patients receiving palliative&#xD;
             radiotherapy to sites of disease that are not measurable may be eligible and should be&#xD;
             discussed with the Chief Investigator.&#xD;
&#xD;
          -  Male/female patients aged ≥18 years.&#xD;
&#xD;
          -  WHO Performance status 0, 1 or 2.&#xD;
&#xD;
          -  Patients should have a projected life expectancy of at least 3 months.&#xD;
&#xD;
          -  Completion of baseline quality of life questionnaire (EORTC QLQ C30).&#xD;
&#xD;
          -  Adequate cardiac function; formal measurement of left ventricular ejection fraction is&#xD;
             only required if clinically indicated.&#xD;
&#xD;
          -  Adequate bone marrow function: absolute neutrophil count (ANC) ≥1.5x109/l; white blood&#xD;
             cell count ≥ 3x109/l; platelets ≥ 100x109/l; haemoglobin (Hb) ≥ 9g/dl (can be&#xD;
             post-transfusion).&#xD;
&#xD;
          -  Adequate renal function: calculated creatinine clearance ≥50ml/minute.&#xD;
&#xD;
          -  Adequate liver function: serum bilirubin ≤1.5x ULN; ALT/AST ≤2.5x ULN; ALP ≤3x ULN (in&#xD;
             the absence of liver metastases). If liver metastases are present, serum transaminases&#xD;
             ≤5x ULN are permitted.&#xD;
&#xD;
          -  Written informed consent must be obtained from the patient before any study-specific&#xD;
             procedures are performed (see Section 12.0).&#xD;
&#xD;
        Note: Epidermal growth factor receptor (EGFR) positivity by immunohistochemistry will not&#xD;
        be required for study entry. Slides obtained from previously collected paraffin embedded&#xD;
        archived specimens will be collected centrally for EGFR staining. A multivariate analysis&#xD;
        will then be performed to exclude any effects of EGFR status on outcome measures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Tumours of squamous histology.&#xD;
&#xD;
          -  Patients with locally advanced oesophageal cancer suitable for definitive&#xD;
             chemoradiotherapy.&#xD;
&#xD;
          -  Documented or symptomatic brain metastases and/or central nervous system metastases or&#xD;
             leptomeningeal disease.&#xD;
&#xD;
          -  Previous chemotherapy or radiotherapy. See Inclusion criteria for note regarding&#xD;
             palliative radiotherapy.&#xD;
&#xD;
          -  Any major surgery within 4 weeks prior to the start of study treatment.&#xD;
&#xD;
          -  Any prior treatment with an EGFR signal transduction directed therapy.&#xD;
&#xD;
          -  Treatment with non-permitted medication.&#xD;
&#xD;
          -  Clinically significant (i.e. active) cardiac disease e.g. symptomatic coronary artery&#xD;
             disease, uncontrolled cardiac dysrhythmia, or myocardial infarction within the last 12&#xD;
             months. Patients with any history of clinically significant cardiac failure are&#xD;
             excluded from study entry.&#xD;
&#xD;
          -  History of interstitial lung disease (e.g., pneumonitis or pulmonary fibrosis) or&#xD;
             evidence of interstitial lung disease on baseline chest CT scan.&#xD;
&#xD;
          -  Known peripheral neuropathy &gt;Grade 1 (absence of deep tendon reflexes as the sole&#xD;
             neurological abnormality does not render the patient ineligible).&#xD;
&#xD;
          -  Lack of physical integrity of the upper gastro-intestinal tract, malabsorption&#xD;
             syndrome, or inability to take oral medication (administration of capecitabine by&#xD;
             naso-gastric or jejunostomy feeding tube is permitted).&#xD;
&#xD;
          -  Known dihydropyrimidine dehydrogenase (DPD) deficiency.&#xD;
&#xD;
          -  Known hypersensitivity to panitumumab, components of the EOX regimen, or any of the&#xD;
             constituents of these agents.&#xD;
&#xD;
          -  Known positive tests for human immunodeficiency virus (HIV) infection, hepatitis C&#xD;
             virus, acute or chronic active hepatitis B infection.&#xD;
&#xD;
          -  Other clinically significant disease or co-morbidity which may adversely affect the&#xD;
             safe delivery of treatment within this trial.&#xD;
&#xD;
          -  Female patients who may be pregnant or breastfeeding. Potential female patients of&#xD;
             childbearing potential must have a negative pregnancy test within 7 days prior to&#xD;
             randomisation, or have had amenorrhea for more than 2 years.&#xD;
&#xD;
          -  Patients of child-bearing potential not consenting to use adequate contraceptive&#xD;
             precautions or abstinence during the course of the study and for 6 months after the&#xD;
             last study drug administration for females, and 1 month for males.&#xD;
&#xD;
          -  Any other malignancies within the last 5 years (other than curatively treated basal&#xD;
             cell carcinoma of the skin and/or in situ carcinoma of the cervix).&#xD;
&#xD;
          -  Treatment with another investigational agent within 30 days of commencing study&#xD;
             treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Prof Cunningham, David</last_name>
    <role>Principal Investigator</role>
    <affiliation>Royal Marsden NHS Foundation Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bournemouth</name>
      <address>
        <city>Bournemouth</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Luke's Guildford</name>
      <address>
        <city>Guildford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Liverpool</name>
      <address>
        <city>Liverpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Marsden NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>SW3 6JJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Newcastle</name>
      <address>
        <city>Newcastle</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Marsden NHS Foundation Trust</name>
      <address>
        <city>Sutton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clatterbridge Oncology Centre</name>
      <address>
        <city>Wirral</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <study_first_submitted>January 16, 2009</study_first_submitted>
  <study_first_submitted_qc>January 16, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 19, 2009</study_first_posted>
  <last_update_submitted>December 10, 2012</last_update_submitted>
  <last_update_submitted_qc>December 10, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 11, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Royal Marsden NHS Foundation Trust</investigator_affiliation>
    <investigator_full_name>Professor David Cunningham</investigator_full_name>
    <investigator_title>Head GI &amp; Lymphoma Units</investigator_title>
  </responsible_party>
  <keyword>epirubicin</keyword>
  <keyword>oxaliplatin</keyword>
  <keyword>capecitabine</keyword>
  <keyword>panitumumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
    <mesh_term>Panitumumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

